Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Table 2 Characteristics of the eligible studies

Study	Smoker (%)		Age (median)		Female (%)		ECOG 0 or 1(%)		Brain metastases (%)		Reported outcomes
Study	Exp	Con	Exp	Con	Exp	Con	Exp	Con	Exp	Con	Reported outcomes
ASCEND-4 [12]	43 35		55 54		54.0 61.0		94 93		31 33		PFS, OS, ORR, Grade ≥ 3 AEs
PROFILE 1014 [7, 25]	39 35		52 54		60.5 63.2		94 95		26 27		PFS, OS, ORR, Grade ≥ 3 AEs
ALEX [10, 26]	40 35		58 54		55.3 57.6		93 93		42 38		PFS, OS, ORR, Grade ≥ 3 AEs
ALTA-1 L [11, 27]	39 46		58 60		50.4 58.7		96 96		29 30		PFS, OS, ORR, Grade ≥ 3 AEs
eXALT3 [13, 28]	40.6 36.1		54 53		49.7 47.6		95.1 95.2		32.9 38.8		PFS, OS, ORR, Grade ≥ 3 AEs
J-ALEX [29,30,31]	46 41		61 59.5		60 61		98 98		14 28		PFS, OS, ORR, Grade ≥ 3 AEs
PROFILE 1029 [32]	25 30.1		48 50		51.9 58.3		96.2 96.1		20.2 31.1		PFS, OS, ORR, Grade ≥ 3 AEs
ALESIA [33]	33 28		51 49		48.8 45.2		97 98		35 37		PFS, ORR, Grade ≥ 3 AEs
CROWN [34]	46 35		61 56		56.0 62.0		98 94		26 27		PFS, OS, ORR, Grade ≥ 3 AEs

Exp, Experiment; Con, Control; PFS, progression free survival; OS, overall survival; ORR, objective response rate; Grade ≥ 3 AEs, adverse events of grade 3 or higher

ISSN: 1471-2407